Mar 22, 2021 · Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month The National Institute for Health and …

Erenumab was further investigated In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was …

Our slide decks bring together extensive clinical trial data supporting the efficacy and safety of the CGRP monoclonal antibodies, erenumab, fremanezumab, galcanezumab and eptinezumab, …

Nov 2, 2020 · Top line results from the Phase 4 HER-MES study of erenumab versus topiramate have demonstrated the superiority of erenumab in migraine prevention. Erenumab had a …

Apr 27, 2021 · The authors stress that this is class IV evidence but conclude that erenumab increased the probability of improved pain control in patients with medication resistant …

Feb 11, 2021 · However, when triptans were used as comparator, a signal of disproportionate reporting for spontaneous abortion was detected in association with erenumab, …

Nov 19, 2020 · Erenumab (AMG 334) Galcanezumab (LY2951742) Fremanezumab (TEV-48125) Eptinezumab (ALD403) Rimegepant (BHV-3000) Ubrogepant (MK-1602) Zavegepant (BHV …

Nov 20, 2023 · ARISE evaluated the efficacy of erenumab 70 mg (as a subcutaneous monthly regimen) in patients with episodic migraine (defined as ≥ 4 to <15 migraine days per month …

Jan 22, 2020 · In both the erenumab and galcanezumab studies, placebo effects were very small. A Phase 1 pharmacokinetics, safety and tolerability study has been published for …

Oct 20, 2021 · For rimegepant there is also evidence showing that the drug is well tolerated when administered with CGRP mAbs. 8,9 In a sub-study of 13 patients from an open-label, long …